论文部分内容阅读
背景和目的:肺癌是慢性阻塞性肺疾病(COPD)患者常见的致死病因。该研究旨在观察吸入糖皮质激素(ICS)能否降低 COPD 患者发生肺癌的风险。对1996年12月至2001年5月在初级诊所登记,符合 ICD-9 COPD 诊断标准,或自诉患有慢性肺部疾病,或曾接受支气管舒张剂治疗的美国退伍军人进行队列研究,入选对象为对 ICS 治疗依从性在80%以上并且入选时未患肺癌的病例。采用 Cox 回归分析,评估使用 ICS 的 COPD 患者发生肺癌的风险及其他混杂因素的影响。结果:通过对10 474例 COPD 患者3.8年的随访
Background and Objective: Lung cancer is a common cause of death in patients with chronic obstructive pulmonary disease (COPD). The aim of this study was to determine if inhaled glucocorticoid (ICS) can reduce the risk of lung cancer in COPD patients. A cohort of U.S. veterans enrolled in primary clinics between December 1996 and May 2001 that met ICD-9 criteria for COPD or who had their own complaint of chronic lung disease or who had received bronchodilator therapy were enrolled in this study Compliance with ICS treatment is over 80% and no lung cancer is present at enrollment. Cox regression analysis was used to assess the risk of developing lung cancer and other confounding factors in COPD patients using ICS. Results: A total of 10 474 COPD patients were followed up for 3.8 years